News Feature

Human TCR-based adoptive T cell cancer therapy is entering clinical testing. Can it succeed in cancers where CAR-T cell therapy has failed?

Chemical synthesis matures as an alternative to cell culture for made-to-order small to medium-sized proteins.

Moving beyond viral vectors and lipid nanoparticles, Spotlight is conjugating Cas proteins to agents that will home endonucleases and their guide RNAs to targets in vivo.

With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions.

China’s growing influence in biotech was underscored in 2020 during a record-breaking year for sector financing.

Ex vivo gene editing of hematopoietic stem cells using CRISPR–Cas9 and adeno-associated virus serotype 6 is ready for trials in people with sickle-cell disease.

Engineered single-strain biotherapeutic products and massive synthetic consortia are being developed in parallel to manipulate the immune and metabolic systems in disease.

Plasma cells can be turned into protein factories for patients with protein deficiencies for whom one-and-done gene therapy is not an option.

Will regulatory T cells provide needed therapies against inflammatory and autoimmune disorders?

Nature Biotechnology asks a selection of leaders from across biotech to look at the future of the sector and make some predictions for the coming years.

Cytokines are problematic drugs, but Stanford structural immunologist Chris Garcia has engineered creative solutions that his company will begin testing this year in cancer

Using single-cell techniques to isolate and characterize IgE-producing B cells that can produce anti-allergy antibodies.

Large-scale genomic studies are reinvigorating interest in a small group of molecularly defined autism-associated disorders and spurring renewed interest in genetic therapies.

For most of its history, biomedical research and clinical testing has neglected over half of the world’s population. Finally, researchers and funders are starting to recognize the importance of sex differences.

In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay.

Despite early failures in the clinic, the idea of anti-aging therapies that purge the body of dying cells is gaining traction with a raft of startups now focused on senescence.

The Chan Zuckerberg Biohub is both an institute and an academic network devoted to accelerating research via cutting edge technologies and open science. Its focus on single-cell analysis and infectious disease has placed it front and center in the pandemic.

Single-cell analysis sheds light on immune response to COVID-19 infection, enables the rapid discovery of antibody leads, and points to ways to get ahead of future pandemics.

Research groups around the globe are looking to see whether urban wastewater monitoring can be integrated into surveillance systems for SARS-CoV-2 and other pathogens.

The University of Washington’s Institute for Protein Design has become a hub to galvanize de novo protein engineering, citizen science and much more since its founding in 2012.